-
Improvements in Scalp Outcomes With Roflumilast Foam 0.3% for Psoriasis of the Scalp and Body From the Phase 3 ARRECTOR Trial
Sep 9, 2025, 16:22 PM -
Comparing HTA Outcomes and Rationale for Decision Making Between Countries With Mature vs. Newly Founded HTA Systems: Evidence From England, France, and Greece
Sep 9, 2025, 16:22 PM -
Treatment Patterns and Healthcare Resource Utilization in Patients With Chronic Inflammatory Demyelinating Polyneuropathy in England: A Retrospective, Observational Cohort Study
Sep 9, 2025, 16:22 PM -
Postmarketing Safety Analysis of Nebivolol in Real-World Settings Using Bioinformatics and Disproportionality Analysis With FDA Adverse Event Reporting System (FAERS) Data
Sep 9, 2025, 16:22 PM -
Integrating Real-World Evidence for Advanced Therapies in Inflammatory Bowel Disease Into Reimbursement Submissions: Insights and Considerations From the UK
Sep 9, 2025, 16:22 PM -
The Artificial Intelligence Era in Health Economic Modeling
Sep 9, 2025, 16:22 PM -
Characterizing Exploratory Endpoints in Early Oncology Trials: Insights From Trial Registry Audit
Sep 9, 2025, 16:22 PM -
The Enduring Economic Burden of COVID-19 and the Value of Vaccination Strategies in High-Income Countries
Sep 9, 2025, 16:22 PM -
Quantifying the Therapeutic Benefit of External Beam Radiotherapy in Uterine Serous Carcinoma: A Real-World Study
Sep 9, 2025, 16:22 PM -
A Systematic Literature Review on Economic Evaluations and Cost-Effectiveness of Second-Line Treatment Options for Immune Thrombocytopenia
Sep 9, 2025, 16:22 PM -
Budget Impact Analysis of Eplerenone For the Management of Heart Failure With Reduced Ejection Fraction (HFrEF) in Italy
Sep 9, 2025, 16:22 PM -
Clinical Functional Profile and Neuroimaging in Cerebral Palsy: A Population-Based Study
Sep 9, 2025, 16:22 PM -
The Alignment Between Technology Incorporations and Actual Health Needs
Sep 9, 2025, 16:22 PM -
Competing Beyond the First Mover: How Late to Market Analogues Navigate Pricing and Access in Major Global Markets
Sep 9, 2025, 16:22 PM -
Importance of Decisional Context in the Health Technology Assessment (HTA) of Ultra-Orphan Drugs
Sep 9, 2025, 16:22 PM -
Archival Sample Testing for Real-World Insights: Innovative Approaches to Enriching Retrospective Studies With Biomarker Data
Sep 9, 2025, 16:22 PM -
Negotiated Closed Budgets in Greece: A Case Study of Success in Enhancing Patient Access Whilst Achieving Savings
Sep 9, 2025, 16:22 PM -
Navigating Uncertainty and Pragmatic Acceptance: Canadian Patient and Public Perspectives on Radiopharmaceutical Therapy in the Context of Whole Health
Sep 9, 2025, 16:22 PM -
Unseen Burdens of Glycogen Storage Disease Type Ia (GSDIa) Experienced by Patients, Caregivers, and their Healthcare Team
Sep 9, 2025, 16:22 PM -
Real-World Study of Breast Cancer Epidemiology and Treatment Patterns: A Pilot Study to Assess EHR-Derived Data in the United Kingdom
Sep 9, 2025, 16:22 PM
